Hematologic Oncology Articles | Page 2

Taking the Next Step in MCL: Novel Combos and Immunotherapy Under Study
Despite advancements in treatment strategies for mantle cell lymphoma, patients experience diminishing responses from sequential lines of therapy as their disease progresses, sharpening the focus on developing new agents and combinations.
The combination of venetoclax and ibrutinib induced a 16-week complete response rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma.
Expert Reviews CLL Advances Presented at ASH
Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.
MCL Leader Discusses Optimal Disease Management
Andre Goy, MD, discusses the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.
FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia
The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Denosumab Approved in Europe for Myeloma
The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.
MRD Prognostic of Poorer Outcomes in AML
Molecular minimal residual disease was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly-diagnosed acute myeloid leukemia.
Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML
Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.
Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months
In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation. 
Ongoing Advances Transforming Treatment in Myeloma
Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.
Publication Bottom Border
Border Publication